Research

Energy balance

No statistically significant associations were identified for SGLT2 inhibitors regarding hematologic malignancy risk.

SGLT2 inhibitors may not pose a risk for hematologic malignancies, making them a safer choice in this regard.

StrongRefutesmedium confidence
No statistically significant associations were identified for SGLT2 inhibitors (i.e., 95%CI across 1.0).
Pao‐Yen Lin et al. · Biomolecules · 2025

Why this rating

Based on a pilot network meta-analysis of randomized controlled trials.

Source

Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis

Pao‐Yen Lin et al. · Biomolecules · 2025

DOI 10.3390/biom15111622

Meta-analysisCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →